Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc.
Your view on XBIO
Overview
What the company does, where it operates, and who runs it.
About Xenetic Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James F. Parslow
- Headquarters
- 40 Speen Street, Framingham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James F. Parslow
- Headquarters
- 40 Speen Street, Framingham, MA, US
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics.
It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies.
It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Xenetic Biosciences, Inc., and the rating behind it. XBIO last traded at $2.19; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Xenetic Biosciences, Inc.. Starting points for Xenetic Biosciences, Inc.: EPS -$1.08, beta 2.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Xenetic Biosciences, Inc.. Xenetic Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Xenetic Biosciences, Inc.. Trailing twelve-month EPS for Xenetic Biosciences, Inc. stands at -$1.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Xenetic Biosciences, Inc.. Xenetic Biosciences, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Xenetic Biosciences, Inc. valued side by side against its closest peers. Xenetic Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Xenetic Biosciences, Inc., and how their positions are changing. At a $5.0M market value, institutional positions materially move Xenetic Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Xenetic Biosciences, Inc. executives and directors. Shares of Xenetic Biosciences, Inc. have traded between $2.20 and $13.93 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Xenetic Biosciences, Inc.. Xenetic Biosciences, Inc. is a $5.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Xenetic Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Xenetic Biosciences, Inc.. Coverage tracks Xenetic Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.